SBI Biotech Co., Ltd.   Report issue

For profit Phase 1
Founded: Tokyo Japan (2001)
Status: Left NME R&D (2014)

Organization Overview

First Clinical Trial
2009
NCT01035216
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

gnkg168 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1